Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...

As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal ...

Weight loss drugs are likely to stay in demand for a long time judging by the obesity trend as shown by latest CDC data ...

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently ...

Chinese biotechnology firms are seeing the wildest swings in months as investors struggle to assess the impact of a US push ...

Existing obesity drugs like Wegovy and Eli Lilly's Zepbound are injectable. Pills require larger amounts of active ...

We recently compiled a list titled Starter Stock Portfolio: 10 Safe Stocks To Invest In Now. In this article, we are going to ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

A probable rate cut has provided hope for the economy. Despite that, the impact on financial markets and stocks remains ...